Neoprobe Corporation (AMEX:NEOP) is developing and commercializing targeted agents aimed at the identification of occult (undetected) disease. Neoprobe was founded in 1983 and is based in Dublin, Ohio. Neoprobe, a biomedical company, engages in the development and commercialization of precision diagnostics that enhance patient care and improve patient benefit.
Neoprobe Corporation yesterday announced that its New Drug Application (NDA) for Lymphoseek® (tilmanocept) has been accepted for review by the U.S. Food and Drug Administration (FDA). Neoprobe submitted the Lymphoseek NDA on August 10, 2011. Neoprobe seeks U.S. clearance to market Lymphoseek for use in Intraoperative Lymphatic Mapping (ILM), a surgical oncology procedure in which lymph nodes draining the area around a tumor are identified and biopsied to determine if cancer has spread to the lymph nodes. According to the American Cancer Society, approximately 230,000 new cases of breast cancer and 70,000 new cases of melanoma are expected to be diagnosed in the United States in 2011.1 The Lymphoseek NDA has proposed use of the agent in anatomic delineation of lymphatic tissue.
?The acceptance of the Lymphoseek NDA filing marks a critical milestone for the clinical and regulatory development of this agent. Lymphoseek has undergone study in two prospective, well- controlled and designed Phase 3 clinical trials under the direction of nearly 30 investigators in more than 500 patients,? said Rodger A. Brown, Vice President, Regulatory Affairs and Quality Assurance, of Neoprobe. ?We look forward to working in collaboration with the FDA to prepare for its pending review of the NDA.?
For more information about Neoprobe, please visit www.neoprobe.com
Read full artical and disclimar at : http://crwepicks.com/?p=18798